Journal article
Comparative assessment of subretinal hyper-reflective material in patients treated with brolucizumab versus aflibercept in HAWK and HARRIER
Abstract
PURPOSE: Post hoc analysis of the phase III HAWK and HARRIER studies to compare the reductions in subretinal hyper-reflective material (SHRM) thickness following brolucizumab 6 mg or aflibercept 2 mg treatment and to assess SHRM thickness and thickness variability as a potential biomarker of visual outcomes in patients with neovascular age-related macular degeneration (nAMD).
METHODS: Optical coherence tomography images from the brolucizumab …
Authors
Sadda S; Sarraf D; Khanani AM; Tadayoni R; Chang AA; Saffar I; Gedif K; Wong DT
Journal
British Journal of Ophthalmology, Vol. 108, No. 6, pp. 852–858
Publisher
BMJ
Publication Date
June 2024
DOI
10.1136/bjo-2023-323577
ISSN
0007-1161
Fields of Research (FoR)
Medical Subject Headings (MeSH)
HumansReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsTomography, Optical CoherenceVisual AcuityAngiogenesis InhibitorsIntravitreal InjectionsWet Macular DegenerationMaleFemaleAntibodies, Monoclonal, HumanizedAgedVascular Endothelial Growth Factor ADouble-Blind MethodRetinaTreatment Outcome